Alzheimer's disease (AD) is a progressive neurodegenerative disease and a leading cause of dementia, profoundly affecting individuals worldwide. However, there are limited therapeutic approaches to treat AD, with current approaches primarily focused on providing symptomatic relief rather than halting the disease progression, highlighting the need for alternative strategies. Nutraceuticals, which are derived from natural sources, offer a promising alternative because of their multi-targeted mechanisms that modulate inflammation, oxidative stress and neurodegeneration, addressing key symptoms of AD pathology. Studies from clinical trials state the challenges of bioavailability and efficacy of nutraceuticals. Advancements and refinements in food processing and delivery methods, along with personalized nutrition, offer a possible approach to overcome these drawbacks. Future directions rely on combination therapies incorporating nutraceuticals to enhance the bioavailability and efficacy of these compounds. This approach could pave way for innovative solutions of elevating nutraceuticals from farm to pharma that offer sustainable solutions to mitigate AD globally.
LampteyRNLChaulagainBTrivediR, et al.A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci2022; 23: 1851.
3.
ChenGFXuTHYanY, et al.Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin2017; 38: 1205–1235.
4.
AbdelnourCAgostaFBozzaliM, et al.Perspectives and challenges in patient stratification in Alzheimer’s disease. Alzheimers Res Ther2022; 14: 112.
5.
KamilaPKarKChowdhuryS, et al.Effect of neuroinflammation on the progression of Alzheimer’s disease and its significant ramifications for novel anti-inflammatory treatments. IBRO Neurosci Rep2025; 18: 771–782.
6.
LambertJCIbrahim-VerbaasCAHaroldD, et al.Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet2013; 45: 1452–1458.
7.
ZhangJZhangYWangJ, et al.Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther2024; 9: 211.
8.
BreijyehZKaramanR. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules2020; 25: 5789.
9.
HampelHHardyJBlennowK, et al.The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry2021; 26: 5481–5503.
10.
YuCCDuYJWangSQ, et al.Experimental evidence of the benefits of acupuncture for Alzheimer’s disease: an updated review. Front Neurosci2020; 14: 549772.
11.
NamYShinSJKumarV, et al.Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies. Transl Neurodegener2025; 14: 15.
12.
BloomGS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol2014; 71: 505–508.
13.
ZhangHWeiWZhaoM, et al.Interaction between aβ and tau in the pathogenesis of Alzheimer’s disease. Int J Biol Sci2021; 17: 2181–2192.
14.
LeeSJCNamELeeHJ, et al.Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors. Chem Soc Rev2017; 46: 310–323.
15.
MiloschNTanriöverGKunduA, et al.Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the akt survival pathway. Cell Death Dis2014; 5: e1391.
16.
WisemanFKPulfordLJBarkusC, et al.Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP. Brain2018; 141: 2457–2474.
17.
O’BrienRJWongPC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci2011; 34: 185–204.
18.
ChenJChenJSLiS, et al.Amyloid precursor protein: a regulatory hub in Alzheimer’s disease. Aging Dis2023; 15: 201–225.
19.
BeataBKWojciechJJohannesK, et al.Alzheimer’s disease—biochemical and psychological background for diagnosis and treatment. Int J Mol Sci2023; 24: 1059.
20.
SongTSongXZhuC, et al.Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: a meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res Rev2021; 72: 101503.
21.
MazouzWHaouliNEHGaliL, et al.Antioxidant, anti-Alzheimer, anti-diabetic, and anti-inflammatory activities of the endemic halophyte Limonium spathulatum (Desf.) kuntze on LPS-stimulated RAW264 macrophages. S Afr J Bot2020; 135: 101–108.
22.
AnandPSinghBSinghN. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease. Bioorg Med Chem2012; 20: 1175–1180.
23.
AnandPSinghB. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res2013; 36: 375–399.
24.
Ferreira-VieiraTHGuimaraesIMSilvaFR, et al.Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol2016; 14: 101–115.
PisaniSMuellerCHuntleyJ, et al.A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer’s disease and mild cognitive impairment with a comparison to donepezil. Int J Geriatr Psychiatry2021; 36: 1471–1487.
27.
KhouryRRajamanickamJGrossbergGT. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. Ther Adv Drug Saf2018; 9: 171–178.
28.
HuangY-JLinCHLaneHY, et al.NMDA Neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s disease. Curr Neuropharmacol2012; 10: 272–285.
29.
Companys-AlemanyJTurcuALBellver-SanchisA, et al.A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice. Pharmaceutics2020; 12: 284.
CummingsJ. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease therapeutics. Drugs2023; 83: 569–576.
32.
KangC. Donanemab: first approval. Drugs2024; 84: 1313–1318.
33.
TeraoIKodamaW. Comparative efficacy, tolerability, and acceptability of donanemab, lecanemab, aducanumab, melatonin, and aerobic exercise for a short time on cognitive function in mild cognitive impairment and mild Alzheimer’s disease: a systematic review and network meta-analysis. J Alzheimers Dis2024; 98: 825–835.
34.
EspayAJKeppKPHerrupK. Lecanemab and donanemab as therapies for Alzheimer’s disease: an illustrated perspective on the data. eNeuro2024; 11: 319–323.
35.
SmithEEPhillipsNAFeldmanHH, et al.Use of lecanemab and donanemab in the Canadian healthcare system: evidence, challenges, and areas for future research. J Prev Alzheimers Dis2025; 12: 100068.
36.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease. JAMA2023; 330: 512.
37.
PaulsMMHBinnieLRBenjaminP, et al.The PASTIS trial: testing tadalafil for possible use in vascular cognitive impairment. Alzheimers Dement2022; 18: 2393–2402.
38.
PengYYuanMXinJ, et al.Screening novel drug candidates for Alzheimer’s disease by an integrated network and transcriptome analysis. Bioinformatics2020; 36: 4626–4632.
39.
WangJHuangSLanG, et al.Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer’s disease in clinical and community cohorts. Alzheimers Dement2025; 21: e70038.
40.
GiaraK.Alpha cognition’s new Alzheimer’s drug could improve tolerability for patients. MedCentral 2024. https://www.medcentral.com/neurology/dementia/alpha-cognitions-new-alzheimers-drug-could-improve-tolerability-for-patients (2024, accessed 1 September 2025).
41.
AndradeSRamalhoMJLoureiroJA, et al.Natural compounds for Alzheimer’s disease therapy: a systematic review of preclinical and clinical studies. Int J Mol Sci2019; 20: 2313.
42.
SilvaRFMPogačnikL. Polyphenols from food and natural products: neuroprotection and safety. Antioxidants2020; 9: 61.
43.
VigneshAAmalTCSarvalingamA, et al.A review on the influence of nutraceuticals and functional foods on health. Food Chem Adv2024; 5: 100749.
44.
ChandraSSaklaniSKumarP, et al.Nutraceuticals: pharmacologically active potent dietary supplements. Biomed Res Int2022; 2022: 2051017.
45.
SachdevaHKhaturiaSChaharM. Nutraceuticals as therapeutic agents for prevention and treatment of diseases. In: In: prebiotics, probiotics and nutraceuticals. Singapore: Springer Nature Singapore, 2022, pp.45–68.
46.
VisenAVisenSSharmaA, et al.Nutraceuticals as a natural alternative for preventive and proactive health care. In: In: functional foods and nutraceuticals in metabolic and non-communicable diseases. London: Elsevier, 2022, pp.603–618.
47.
GhaffariSRoshanravanN. The role of nutraceuticals in prevention and treatment of hypertension: an updated review of the literature. Food Res Int2020; 128: 108749.
48.
BhullarKSRupasingheHP. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev2013; 2013: 891748.
49.
JalouliMRahmanMABiswasP, et al.Targeting natural antioxidant polyphenols to protect neuroinflammation and neurodegenerative diseases: a comprehensive review. Front Pharmacol2025; 16: 1492517.
50.
JabirNRKhanFRTabrezS. Cholinesterase targeting by polyphenols: a therapeutic approach for the treatment of Alzheimer’s disease. CNS Neurosci Ther2018; 24: 753–762.
51.
ChhabraSBakshiAKaurR. Role of nutraceuticals in health promotion and disease prevention: a review in the Indian context. Curr Top Nutraceutical Res2021; 19: 139–145.
52.
VolpeRSotisG. Nutraceuticals: definition and epidemiological rationale for their use in clinical practice. High Blood Press Cardiovasc Prev2015; 22: 199–201.
53.
AmievaHMeillonCHelmerC, et al.Ginkgo Biloba extract and long-term cognitive decline: a 20-year follow-up population-based study. PLoS One2013; 8: e52755.
54.
ChowdhuryDRoyAKReddyVR, et al.Multicenter, open-label, prospective study shows safety and therapeutic benefits of a defined ginkgo biloba extract for adults with major neurocognitive disorder. Dement Geriatr Cogn Disord2024; 53: 299–309.
55.
WangZDengYZhouT, et al.Effects of natural extracts in cognitive function of healthy adults: a systematic review and network meta-analysis. Front Pharmacol2025; 16: 1573034.
56.
DasSSGopalPMThomasJV, et al.Influence of CurQfen®-curcumin on cognitive impairment: a randomized, double-blinded, placebo-controlled, 3-arm, 3-sequence comparative study. Front Dement2023; 2: 1222708.
57.
ZhangLYangSWongLR, et al.In vitro and in vivo comparison of curcumin-encapsulated chitosan-coated poly(lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s disease. Mol Pharm2020; 17: 4256–4269.
58.
Sadegh MalvajerdSAzadiAIzadiZ, et al.Brain delivery of curcumin using solid lipid nanoparticles and nanostructured lipid carriers: preparation, optimization, and pharmacokinetic evaluation. ACS Chem Neurosci2019; 10: 728–739.
59.
WangCYZhengWWangT, et al.Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacology2011; 36: 1073–1089.
60.
RafiiMSWalshSLittleJT, et al.A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology2011; 76: 1389–1394.
61.
DyskenMWSanoMAsthanaS, et al.Effect of vitamin E and memantine on functional decline in Alzheimer disease. JAMA2014; 311: 33.
62.
RemingtonRBechtelCLarsenD, et al.A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer’s disease. J Alzheimers Dis2015; 45: 395–405.
63.
XiaNDaiberAFörstermannU, et al.Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol2017; 174: 1633–1646.
FiccoDBMPetroniKMisturaL, et al.Polyphenols in cereals: state of the art of available information and its potential use in epidemiological studies. Nutrients2024; 16: 2155.
66.
ZhangZLiXSangS, et al.Polyphenols as plant-based nutraceuticals: health effects, encapsulation, nano-delivery, and application. Foods2022; 11: 2189.
67.
GodosJRapisardaGMarventanoS, et al.Association between polyphenol intake and adherence to the Mediterranean diet in Sicily, southern Italy. NFS J2017; 8: 1–7.
68.
PasquetPLJulien-DavidDZhaoM, et al.Stability and preservation of phenolic compounds and related antioxidant capacity from agro-food matrix: effect of pH and atmosphere. Food Biosci2024; 57: 103586.
69.
WilliamsonG. Bioavailability of food polyphenols: current state of knowledge. Annu Rev Food Sci Technol2025; 16: 315–332.
70.
Winiarska-MieczanAKwiecieńMJachimowicz-RogowskaK, et al.Anti-inflammatory, antioxidant, and neuroprotective effects of polyphenols—polyphenols as an element of diet therapy in depressive disorders. Int J Mol Sci2023; 24: 2258.
71.
KimJKimJ. Green tea, coffee, and caffeine consumption are inversely associated with self-report lifetime depression in the Korean population. Nutrients2018; 10: 1201.
72.
BouyahyaAOmariNEEl HachlafiN, et al.Chemical compounds of berry-derived polyphenols and their effects on gut microbiota, inflammation, and cancer. Molecules2022; 27: 3286.
73.
AgarwalPHollandTMJamesBD, et al.Pelargonidin and berry intake association with Alzheimer’s disease neuropathology: a community-based study. J Alzheimers Dis2022; 88: 653–661.
74.
GolovinskaiaOWangCK. Review of functional and pharmacological activities of berries. Molecules2021; 26: 3904.
75.
KhooHEAzlanATangST, et al.Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr Res2017; 61: 1361779.
76.
NorouzkhaniNAfshariSSadatmadaniSF, et al.Therapeutic potential of berries in age-related neurological disorders. Front Pharmacol2024; 15: 1348127.
77.
PattedPGMasareddyRSPatilAS, et al.Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits. Futur J Pharm Sci2024; 10: 94.
78.
DighririIMAlsubaieAMHakamiFM, et al.Effects of omega-3 polyunsaturated fatty acids on brain functions: a systematic review. Cureus2022; 14: e30091.
79.
BlondeauN. The nutraceutical potential of omega-3 alpha-linolenic acid in reducing the consequences of stroke. Biochimie2016; 120: 49–55.
80.
ChenCHuangHDaiQQ, et al.Fish consumption, long-chain omega-3 fatty acids intake and risk of stroke: an updated systematic review and meta-analysis. Asia Pac J Clin Nutr2021; 30: 140–152.
81.
GuptaJGuptaR. Nutraceutical status and scientific strategies for enhancing production of omega-3 fatty acids from microalgae and their role in healthcare. Curr Pharm Biotechnol2020; 21: 1616–1631.
82.
PuriVNagpalMSinghI, et al.A comprehensive review on nutraceuticals: therapy support and formulation challenges. Nutrients2022; 14: 4637.
83.
AmanullahMNahidMHosenSZ, et al.The nutraceutical value of foods and its health benefits: a review. Health Dynamics2024; 1: 273–283.
84.
DasPDuttaAPanchaliT, et al.Advances in therapeutic applications of fish oil: a review. Meas Food2024; 13: 100142.
85.
HuangYDengYZhangP, et al.Associations of fish oil supplementation with incident dementia: evidence from the UK Biobank cohort study. Front Neurosci2022; 16: 910977.
86.
NowakWJeziorekM. The role of flaxseed in improving human health. Healthcare2023; 11: 395.
87.
KauserSHussainAAshrafS, et al.Flaxseed (Linum usitatissimum); phytochemistry, pharmacological characteristics and functional food applications. Food Chem Adv2024; 4: 100573.
88.
ManimuruganCSujathaMRathnakumarAL, et al.Role of flaxseed (Linum usitatissimum L.) in disease prevention and treatment. Asian Pac J Trop Biomed2023; 13: 277–286.
89.
KaurHKaurGAliSA. Dairy-based probiotic-fermented functional foods: an update on their health-promoting properties. Fermentation2022; 8: 425.
90.
LatifAShehzadANiaziS, et al.Probiotics: mechanism of action, health benefits and their application in food industries. Front Microbiol2023; 14: 1216674.
91.
DamiánMRCortes-PerezNGQuintanaET, et al.Functional foods, nutraceuticals and probiotics: a focus on human health. Microorganisms2022; 10: 1065.
92.
HemarajataPVersalovicJ. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol2013; 6: 39–51.
93.
NaomiREmbongHOthmanF, et al.Probiotics for Alzheimer’s disease: a systematic review. Nutrients2021; 14: 20.
94.
RutschAKantsjöJBRonchiF. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol2020; 11: 604179.
95.
WangDWangTLiZ, et al.Green tea polyphenols upregulate the Nrf2 signaling pathway and suppress oxidative stress and inflammation markers in D-Galactose-induced liver aging in mice. Front Nutr2022; 9: 836112.
96.
WenPSunZGouF, et al.Oxidative stress and mitochondrial impairment: key drivers in neurodegenerative disorders. Ageing Res Rev2025; 104: 102667.
97.
TruongVLJeongWS. Antioxidant and anti-inflammatory roles of tea polyphenols in inflammatory bowel diseases. Food Sci Hum Wellness2022; 11: 502–511.
98.
MaqboolMZehraviM. Neuroprotective role of polyphenols in treatment of neurological disorders: a review. Interv Pain Med Neuromodulation2021; 1: e117170.
99.
Arias-SánchezRATornerLFenton NavarroB. Polyphenols and neurodegenerative diseases: potential effects and mechanisms of neuroprotection. Molecules2023; 28: 5415.
100.
MoralesICerda-TroncosoCAndradeV, et al.The natural product curcumin as a potential coadjuvant in Alzheimer’s treatment. J Alzheimers Dis2017; 60: 451–460.
101.
ShiHZhaoY. Modulation of tau pathology in Alzheimer’s disease by dietary bioactive compounds. Int J Mol Sci2024; 25: 831.
102.
EgeD. Action mechanisms of curcumin in Alzheimer’s disease and its brain targeted delivery. Materials (Basel)2021; 14: 3332.
103.
VenigallaMSonegoSGyengesiE, et al.Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem Int2016; 95: 63–74.
104.
DeyamaSKanedaKMinamiM. Resolution of depression: antidepressant actions of resolvins. Neurosci Res2022; 211: 85–92.
105.
GiacobbeJBenoitonBZunszainP, et al.The anti-inflammatory role of Omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative, and neurological disorders. Front Psychiatry2020; 11: 122.
106.
GiauVWuSJamerlanA, et al.Gut microbiota and their neuroinflammatory implications in Alzheimer’s disease. Nutrients2018; 10: 1765.
107.
HillJMLukiwWJ. Microbial-generated amyloids and Alzheimer’s disease (AD). Front Aging Neurosci2015; 7: 9.
108.
TingYJiangYHoCT, et al.Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals. J Funct Foods2014; 7: 112–128.
109.
McClementsDJ. Nanoscale nutrient delivery systems for food applications: improving bioactive dispersibility, stability, and bioavailability. J Food Sci2015; 80: N1602–N1611.
110.
McClementsDJXiaoH. Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and nutraceuticals. Food Funct2014; 5: 1320–1333.
111.
ZouLZhengBZhangR, et al.Enhancing the bioaccessibility of hydrophobic bioactive agents using mixed colloidal dispersions: curcumin-loaded zein nanoparticles plus digestible lipid nanoparticles. Food Res Int2016; 81: 74–82.
112.
SalehMMohamedJRubyJ, et al.Preparation of memantine-loaded chitosan nanocrystals: in vitro and ex vivo toxicity analysis. Crystals (Basel)2022; 13: 21.
113.
VohraMAmirMSharmaA, et al.Formulation strategies for nose-to-brain drug delivery in Alzheimer’s disease. Health Sci Rev2023; 6: 100075.
114.
RahmanianNJafariSMWaniTA. Bioactive profile, dehydration, extraction and application of the bioactive components of olive leaves. Trends Food Sci Technol2015; 42: 150–172.
115.
RezaeiAFathiMJafariSM. Nanoencapsulation of hydrophobic and low-soluble food bioactive compounds within different nanocarriers. Food Hydrocoll2019; 88: 146–162.
116.
D’ArchivioMFilesiCVarìR, et al.Bioavailability of the polyphenols: status and controversies. Int J Mol Sci2010; 11: 1321–1342.
117.
AguileraJM. The food matrix: implications in processing, nutrition and health. Crit Rev Food Sci Nutr2019; 59: 3612–3629.
118.
DimaCAssadpourEDimaS, et al.Bioavailability of nutraceuticals: role of the food matrix, processing conditions, the gastrointestinal tract, and nanodelivery systems. Compr Rev Food Sci Food Saf2020; 19: 954–994.
119.
TomasMJafariSM. Influence of food processing operations on vitamins. In: In: encyclopedia of food chemistry. Amsterdam: Elsevier, 2019, pp.129–139.
120.
PathakMSagarNA. Influence of thermal treatments, extraction methods, and storage conditions on lycopene content of foods. J Food Qual2023; 2023: 1–13.
121.
SensoyI. A review on the relationship between food structure, processing, and bioavailability. Crit Rev Food Sci Nutr2014; 54: 902–909.
122.
ZhangZQiuCLiX, et al.Advances in research on interactions between polyphenols and biology-based nano-delivery systems and their applications in improving the bioavailability of polyphenols. Trends Food Sci Technol2021; 116: 492–500.
123.
CummingsJLOsseAMLKinneyJW, et al.Alzheimer’s disease: combination therapies and clinical trials for combination therapy development. CNS Drugs2024; 38: 613–624.
124.
WangADasPSwitzerRC, et al.Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of Amyloid-β immunotherapy. J Neurosci2011; 31: 4124–4136.
125.
SallowaySPSevingyJBudurK, et al.Advancing combination therapy for Alzheimer’s disease. Alzheimers Dement (N Y)2020; 6: e12073.
126.
YounHLeeKJKimSG, et al.The behavioral effects of combination therapy of memantine and acetylcholinesterase inhibitors compared with acetylcholinesterase inhibitors alone in patients with moderate Alzheimer’s dementia: a double-blind randomized placebo-controlled trial. Psychiatry Investig2021; 18: 233–240.
127.
PatelLGrossbergGT. Combination therapy for Alzheimer’s disease. Drugs Aging2011; 28: 539–546.
128.
KabirMTUddinMSMamunAA, et al.Combination drug therapy for the management of Alzheimer’s disease. Int J Mol Sci2020; 21: 3272.
129.
GuoJWangZLiuR, et al.Memantine, donepezil, or combination therapy-what is the best therapy for Alzheimer’s disease? A network meta-analysis. Brain Behav2020; 10: e01831.
130.
SingarSNagpalRArjmandiBH, et al.Personalized nutrition: tailoring dietary recommendations through genetic insights. Nutrients2024; 16: 2673.
131.
RouskasKGuelaMPantouraM, et al.The influence of an AI-driven personalized nutrition program on the human gut microbiome and its health implications. Nutrients2025; 17: 1260.
132.
LagoumintzisGPatrinosGP. Triangulating nutrigenomics, metabolomics and microbiomics toward personalized nutrition and healthy living. Hum Genomics2023; 17: 109.
133.
GermanJBZivkovicAMDallasDC, et al.Nutrigenomics and personalized diets: what will they mean for food?Annu Rev Food Sci Technol2011; 2: 97–123.
134.
HeskethJ. Personalised nutrition: how far has nutrigenomics progressed?Eur J Clin Nutr2013; 67: 430–435.
135.
AlekhyaLLukalapuPKusuma LathaL, et al.Nutraceuticals: regulatory landscape, clinical evidence, challenges, nutrivigilance in India. Res J Sci Technol2024; 16: 245–254.
136.
BoseASharmaS. Global regulatory trends and comparative insights: nutraceuticals in the USA, India, and Europe. PharmaNutrition2025; 31: 100430.
137.
TomarSMusyuniPAggarwalG. An overview of regulation for nutraceuticals and concept of personalized nutraceuticals. J Generic Med2023; 19: 66–74.
138.
BlazeJ. A comparison of current regulatory frameworks for nutraceuticals in Australia, Canada, Japan, and the United States. Innov Pharm2021; 12: 1–18. doi: 10.24926/iip.v12i2.3694.
139.
TutelyanVASukhanovBPKochetkovaAA, et al.Russian Regulations on nutraceuticals, functional foods, and foods for special dietary uses. In: Nutraceutical and functional food regulations in the United States and around the world. Amsterdam: Elsevier, 2019, pp.399–416.
140.
Sharma Vikesh KumarS. An exhaustive review on regulatory pathway for the approval of nutraceuticals as per India, USA & Japan. Int J Sci Res2024; 13: 410–416.
141.
Le BlochJRouaultMLanghiC, et al.The novel food evaluation process delays access to food innovation in the European Union. NPJ Sci Food2025; 9: 117.
142.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Products, Nutrition, et al.Guidance on the preparation and submission of an application for authorisation of a novel food in the context of regulation (EU) 2015/2283 (revision 1)2. EFSA J2021; 19: e06555.
143.
RamdasiVLingalaDMacharamK, et al.Nutraceutical regulations in India: a comprehensive review. Int J Drug Regul Aff2023; 11: 80–86.
144.
MukhijaMJoshiBCBajwaPS. Regulatory aspects and bottlenecks for nutraceuticals. In: Synbiotics in human health: biology to drug delivery. Singapore: Springer Nature Singapore, 2024, pp.663–677.
145.
SilpiC. Nutraceuticals traditional practices, regulatory guidelines, opportunities and challenges. Discover Food2025; 5: 191.
